Steris plc

STE

NYSE; healthcare; SIC 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies; CIK 0001757898

B

second fifth of 369 graded peers in healthcare

rank 112 of 369; percentile 30.2; sampling error 2.5 points; lower is stronger

A B C D E

B, the elk



Scoreboard

Profitability	B/C	percentile 40.6
Solvency	C	percentile 45.5
Growth and financing	B/C	percentile 40.4
Reliability	0.94 AUC	filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year	Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets	total assets $10.7B
Standard universe	inside	revenue above $1M and assets above $10M
Warnings	none triggered	not computable: distress
Inputs computable	10 of 14	
Graded from	filings received through May 29, 2026	159 days before the rescan; latest periodic filing 10-Q received Aug 7, 2026
Last close	$231.15	2026-11-03; market equity $22.5B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received May 29, 2026

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. We offer our Customers a unique mix of innovative products and services.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 40.6						
Gross profitability	24.5%	32.4%		57.7	365	2026-03-31
Return on invested capital	not computable	9.3%				
latest aligned inputs end 2021-03-31; latest annual assets end 2026-03-31						
Accruals ratio	(5.4%)	(6.6%)		60.5	803	2026-03-31
Gross margin stability, five years	0.5 pts	2.8 pts		3.7	242	2026-03-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Solvency, sleeve percentile 45.5						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	4.50	(0.35)		20.5	747	2026-03-31
Net debt to EBITDA	not computable	1.82x				
latest aligned inputs end 2021-03-31; latest annual assets end 2026-03-31						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2024-03-31; latest annual assets end 2026-03-31						
Current ratio	2.09x	2.92x		70.5	828	2026-03-31
Growth and financing, sleeve percentile 40.4						
Revenue growth, three-year compound	9.4%	10.1%		52.1	412	2026-03-31
Free cash flow growth, three-year compound	35.0%	10.9%		28.4	96	2026-03-31
Reinvestment rate	18.6%	37.1%		60.2	104	2026-03-31
Asset growth, three years	(0.3%)	2.2%		51.9	697	2026-03-31
Net share issuance, one year	(0.8%)	2.5%		9.5	632	2026-05-27

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
107	Healthcare Services Group Inc. (HCSG)	28.8	B	
108	Cytokinetics Inc. (CYTK)	29.1	B	short runway
109	Cadre Holdings, Inc. (CDRE)	29.3	B	
110	MSA Safety Inc. (MSA)	29.6	B	
111	Agios Pharmaceuticals, Inc. (AGIO)	29.9	B	short runway
112	Steris plc (STE)	30.2	B	
113	Tandem Diabetes Care Inc. (TNDM)	30.4	B	
114	BioNexus Gene Lab Corp. (BGLC)	30.7	B	dilution, late filer
115	Avalo Therapeutics, Inc. (AVTX)	31.0	B	dilution, degenerate inputs
116	Verastem, Inc. (VSTM)	31.2	B	dilution, fortress balance sheet
117	Arcutis Biotherapeutics, Inc. (ARQT)	31.5	B	

What the price implies

at the 2026-11-03 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(10.4%)	(2.2%)	44
Distance from 52-week high	(13.9%)	(29.8%)	70
EBIT to enterprise value	4.6%	(1.5%)	77
Free cash flow yield	4.3%	(0.9%)	79
Book value to price	0.32	0.28	54
Sales to price	0.26	0.30	45
Composite equity issuance, five years	9.1%	20.5%	38
Relative strength against the sector, log excess return	(0.28)	(0.19)	44

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 9 of 9, period end 2026-03-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$482.3M
Operating cash flow, four quarters	$1.3B
Months of runway	not finite
Days since last periodic filing	89 (10-Q received Aug 7, 2026)
Median daily dollar volume, 63 sessions	$133.9M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$2.6B	2026-03-31	2026-05-29	10-K	26-039136
2	assets	us-gaap:Assets	$10.7B	2026-03-31	2026-05-29	10-K	26-039136
3	operating income	us-gaap:OperatingIncomeLoss	$548.4M	2021-03-31	2023-05-26	10-K	23-000005
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$517.5M	2021-03-31	2021-05-28	10-K	21-000017
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$120.7M	2021-03-31	2023-05-26	10-K	23-000005
6	total debt	us-gaap:LongTermDebt	$1.7B	2021-03-31	2022-05-31	10-K	22-000011
7	book equity	us-gaap:StockholdersEquity	$3.9B	2021-03-31	2022-05-31	10-K	22-000011
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$220.5M	2021-03-31	2021-05-28	10-K	21-000017
9	total debt	us-gaap:LongTermDebt	$1.2B	2020-03-31	2021-05-28	10-K	21-000017
10	book equity	us-gaap:StockholdersEquity	$3.4B	2020-03-31	2021-05-28	10-K	21-000017
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$319.6M	2020-03-31	2021-05-28	10-K	21-000017
12	net income	us-gaap:NetIncomeLoss	$782.3M	2026-03-31	2026-05-29	10-K	26-039136
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.3B	2026-03-31	2026-05-29	10-K	26-039136
14	assets	us-gaap:Assets	$10.1B	2025-03-31	2026-05-29	10-K	26-039136
15	revenue	us-gaap:Revenues	$5.9B	2026-03-31	2026-05-29	10-K	26-039136
16	gross profit	us-gaap:GrossProfit	$2.4B	2025-03-31	2026-05-29	10-K	26-039136
17	revenue	us-gaap:Revenues	$5.5B	2025-03-31	2026-05-29	10-K	26-039136
18	gross profit	us-gaap:GrossProfit	$2.2B	2024-03-31	2026-05-29	10-K	26-039136
19	revenue	us-gaap:Revenues	$5.1B	2024-03-31	2026-05-29	10-K	26-039136
20	gross profit	us-gaap:GrossProfit	$2.0B	2023-03-31	2025-05-29	10-K	25-000005
21	revenue	us-gaap:Revenues	$4.5B	2023-03-31	2025-05-29	10-K	25-000005
22	gross profit	us-gaap:GrossProfit	$1.9B	2022-03-31	2024-05-29	10-K	24-000008
23	revenue	us-gaap:Revenues	$4.2B	2022-03-31	2024-05-29	10-K	24-000008
24	current assets	us-gaap:AssetsCurrent	$2.4B	2026-03-31	2026-05-29	10-K	26-039136
25	current liabilities	us-gaap:LiabilitiesCurrent	$1.1B	2026-03-31	2026-05-29	10-K	26-039136
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$3.0B	2026-03-31	2026-05-29	10-K	26-039136
27	operating income	us-gaap:OperatingIncomeLoss	$1.1B	2026-03-31	2026-05-29	10-K	26-039136
28	book equity	us-gaap:StockholdersEquity	$7.2B	2026-03-31	2026-05-29	10-K	26-039136
29	liabilities	us-gaap:Liabilities	$3.5B	2026-03-31	2026-05-29	10-K	26-039136
30	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$219.2M	2021-03-31	2023-05-26	10-K	23-000005
31	operating income	us-gaap:OperatingIncomeLoss	$836.1M	2024-03-31	2026-05-29	10-K	26-039136

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

32	interest expense	us-gaap:InterestExpense	$144.4M	2024-03-31	2024-05-29	10-K	24-000008
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$369.0M	2026-03-31	2026-05-29	10-K	26-039136
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$1.1B	2025-03-31	2026-05-29	10-K	26-039136
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$370.1M	2025-03-31	2026-05-29	10-K	26-039136
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$973.3M	2024-03-31	2026-05-29	10-K	26-039136
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$360.3M	2024-03-31	2026-05-29	10-K	26-039136
38	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$756.9M	2023-03-31	2025-05-29	10-K	25-000005
39	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$362.0M	2023-03-31	2025-05-29	10-K	25-000005
40	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$486.5M	2026-03-31	2026-05-29	10-K	26-039136
41	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$1.0B	2026-03-31	2026-05-29	10-K	26-039136
42	income tax	us-gaap:IncomeTaxExpenseBenefit	$262.2M	2026-03-31	2026-05-29	10-K	26-039136
43	current assets	us-gaap:AssetsCurrent	$2.0B	2025-03-31	2026-05-29	10-K	26-039136
44	current liabilities	us-gaap:LiabilitiesCurrent	$1.0B	2025-03-31	2026-05-29	10-K	26-039136
45	assets	us-gaap:Assets	$11.1B	2024-03-31	2025-05-29	10-K	25-000005
46	assets	us-gaap:Assets	$10.8B	2023-03-31	2024-05-29	10-K	24-000008
47	shares outstanding	dei:EntityCommonStockSharesOutstanding	97,602,485	2026-05-27	2026-05-29	10-K	26-039136
48	shares outstanding	dei:EntityCommonStockSharesOutstanding	98,372,310	2025-05-27	2025-05-29	10-K	25-000005

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.